Retinopathy Of Prematurity - Pipeline Review, H2 2018

Publisher Name :
Date: 18-Sep-2018
No. of pages: 46
Inquire Before Buying

Retinopathy Of Prematurity - Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Retinopathy Of Prematurity - Pipeline Review, H2 2018, provides an overview of the Retinopathy Of Prematurity (Ophthalmology) pipeline landscape.

Retinopathy of prematurity (ROP) is a disease that affects immature vasculature in the eyes of premature babies. This disorder which usually develops in both eyes is one of the most common causes of visual loss in childhood and can lead to lifelong vision impairment and blindness Risk factors for the development of ROP include prematurity, extremely low-birth-weight, and multiple births..

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Retinopathy Of Prematurity - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Retinopathy Of Prematurity (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Retinopathy Of Prematurity (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Retinopathy Of Prematurity and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Preclinical stages are 1, 2 and 7 respectively.

Retinopathy Of Prematurity (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Retinopathy Of Prematurity (Ophthalmology).

- The pipeline guide reviews pipeline therapeutics for Retinopathy Of Prematurity (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Retinopathy Of Prematurity (Ophthalmology) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Retinopathy Of Prematurity (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Retinopathy Of Prematurity (Ophthalmology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Retinopathy Of Prematurity (Ophthalmology).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Retinopathy Of Prematurity (Ophthalmology) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Retinopathy Of Prematurity - Pipeline Review, H2 2018

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Retinopathy Of Prematurity - Overview
Retinopathy Of Prematurity - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Retinopathy Of Prematurity - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Retinopathy Of Prematurity - Companies Involved in Therapeutics Development
D. Western Therapeutics Institute Inc
F. Hoffmann-La Roche Ltd
Insmed Inc
Protheragen Inc
Recordati SpA
Retinopathy Of Prematurity - Drug Profiles
Drug for Retinopathy of Prematurity - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
mecasermin rinfabate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Inhibit SCG3 for Diabetic Retinopathy and Retinopathy of Prematurity - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Inhibit SCG3 for Metabolic Disorders, Oncology and Ophthalmology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Neuroprotectin D1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
propranolol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ranibizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Retinopathy of Prematurity - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides to Inhibit TREM-1 for Oncology, Sepsis, Rheumatoid Arthritis, Retinopathy Of Prematurity and Hemorrhagic Shock - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
vitamin A palmitate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Retinopathy Of Prematurity - Dormant Projects
Retinopathy Of Prematurity - Product Development Milestones
Featured News & Press Releases
Jun 30, 2016: Shire Announces Top-Line Results for Phase 2 Trial of SHP607 in Extremely Premature Infants
Jan 21, 2009: Insmed And Premacure Announce European Orphan Designation For IPLEX In Retinopathy Of Prematurity In Infants
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Retinopathy Of Prematurity, H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Number of Products by Stage and Target, H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Retinopathy Of Prematurity - Pipeline by D. Western Therapeutics Institute Inc, H2 2018
Retinopathy Of Prematurity - Pipeline by F. Hoffmann-La Roche Ltd, H2 2018
Retinopathy Of Prematurity - Pipeline by Insmed Inc, H2 2018
Retinopathy Of Prematurity - Pipeline by Protheragen Inc, H2 2018
Retinopathy Of Prematurity - Pipeline by Recordati SpA, H2 2018
Retinopathy Of Prematurity - Dormant Projects, H2 2018

List of Figures
Number of Products under Development for Retinopathy Of Prematurity, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products by Top 10 Targets, H2 2018
Number of Products by Stage and Top 10 Targets, H2 2018
Number of Products by Top 10 Mechanism of Actions, H2 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Top 10 Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018
  • Global Artificial Tears Market Research Report 2024
    Published: 08-Jan-2024        Price: US 2900 Onwards        Pages: 91
    Artificial tears are lubricant eye drops used to treat The dryness and irritation associated with deficient tear production in keratoconjunctivitis sicca (dry eyes). They are also used to moisten contact lenses and in eye examinations. The global Artificial Tears market was valued at US$ 2921.6 million in 2023 and is anticipated to reach US$ 5240.1 million by 2030, witnessing a CAGR of 8.6% during The forecast period 2024-2030. The industry's leading producers are Aller......
  • Global Contact Lens Solution Market Research Report 2024
    Published: 08-Jan-2024        Price: US 2900 Onwards        Pages: 96
    Contact lens solution is a kind of solution that is used to contact lens with The function of cleaning, disinfection, rinsing or preservation, it can also alleviate The eyeball discomfort which caused by wear The contact lens. Contact lens solution can direct contact eyeball, so it must be accord with industrial standard. The global Contact Lens Solution market was valued at US$ 4087.6 million in 2023 and is anticipated to reach US$ 5323.5 million by 2030, witnessing a CAGR of 3.8% ......
  • Global Latanoprost Market Research Report 2024
    Published: 08-Jan-2024        Price: US 2900 Onwards        Pages: 82
    Latanoprost drops is a clear colorless liquid and a medication used to treat increased pressure inside The eye. Onset of effects is usually within four hours, and they last for up to a day. Latanoprost is used to treat high pressure inside The eye due to glaucoma (open angle type) or other eye diseases (e.g., ocular hypertension). It is similar to a natural chemical in The body (prostaglandin) and works by regulating The flow of fluid within The eye which results in lower pressure. Lowerin......
  • Global Contact Lens Solution Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 04-Jan-2024        Price: US 3380 Onwards        Pages: 99
    Market Overview of Global Contact Lens Solution market: According to our latest research, the global Contact Lens Solution market looks promising in the next 5 years. As of 2022, the global Contact Lens Solution market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years. This report covers a research time span from 2018 to 2028, and presents a deep and comprehensive analysis of the global Contact ......
  • Global Dry Eye Syndrome Drugs Market Research Report 2024
    Published: 04-Jan-2024        Price: US 2900 Onwards        Pages: 82
    The Dry Eye Syndrome Drugs market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Dry Eye Syndrome Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive......
  • Global Eye Drops & Lubricants Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 112
    According to our LPI (LP Information) latest study, the global Eye Drops & Lubricants market size was valued at US$ 8841.8 million in 2023. With growing demand in downstream market, the Eye Drops & Lubricants is forecast to a readjusted size of US$ 9780.8 million by 2030 with a CAGR of 1.5% during review period. The research report highlights the growth potential of the global Eye Drops & Lubricants market. Eye Drops & Lubricants are expected to show stable growth in the future market. H......
  • Global Conjunctivitis Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 98
    According to our LPI (LP Information) latest study, the global Conjunctivitis market size was valued at US$ 3482.7 million in 2023. With growing demand in downstream market, the Conjunctivitis is forecast to a readjusted size of US$ 3908 million by 2030 with a CAGR of 1.7% during review period. The research report highlights the growth potential of the global Conjunctivitis market. Conjunctivitis are expected to show stable growth in the future market. However, product differentiation, r......
  • Global Contact Lens Solution Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 118
    According to our LPI (LP Information) latest study, the global Contact Lens Solution market size was valued at US$ 3998.7 million in 2023. With growing demand in downstream market, the Contact Lens Solution is forecast to a readjusted size of US$ 5241.5 million by 2030 with a CAGR of 3.9% during review period. The research report highlights the growth potential of the global Contact Lens Solution market. Contact Lens Solution are expected to show stable growth in the future market. Howev......
  • Global Latanoprost Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 90
    According to our LPI (LP Information) latest study, the global Latanoprost market size was valued at US$ 1344.2 million in 2023. With growing demand in downstream market, the Latanoprost is forecast to a readjusted size of US$ 1574.2 million by 2030 with a CAGR of 2.3% during review period. The research report highlights the growth potential of the global Latanoprost market. Latanoprost are expected to show stable growth in the future market. However, product differentiation, reducing co......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs